This $9 SpaceX Stock Has Crazy Potential

Key Concepts

• SpaceX IPO: Anticipated as the largest IPO in history, expected to drive massive capital inflows into the space sector.
• Story Value vs. Fundamental Value: The distinction between market hype (narrative-driven) and long-term financial performance.
• SpaceX Supply Chain: A multi-layered ecosystem spanning launch hardware, satellite manufacturing, ground infrastructure, semiconductors, and software.
• Asymmetric Opportunity: Identifying undervalued stocks with direct SpaceX exposure that have not yet experienced a "rerating" (valuation increase).
• Micro-needle Chemotherapy: A novel, non-invasive drug delivery system for basal cell carcinoma (BCC).

---

1. The SpaceX IPO and Market Dynamics

The upcoming SpaceX IPO is projected to trigger a massive influx of capital into the space industry. The speaker emphasizes that Wall Street is currently prioritizing "proximity to the story" over traditional valuation metrics like discounted cash flow models.

• The Playbook: Institutional investors are buying into "SpaceX-adjacent" stocks. The speaker warns of an "anticipatory run" followed by a post-IPO correction as institutions take profits.
• Strategic Insight: Investors should distinguish between short-term narrative-driven gains and long-term fundamental value.

2. The SpaceX Supply Chain Breakdown

SpaceX operates as three distinct businesses: Launch (Falcon 9, Starship), Constellation (Starlink), and Defense/Services (Starshield). The supply chain is categorized as follows:

• Launch Hardware: Industrial gas suppliers (Air Liquide, Linde) and high-temperature alloy manufacturers (ATI Inc., Haynes International).
• Satellite Manufacturing: Solar arrays (Redwire), propulsion systems (Aerojet Rocketdyne, Phase Four), and radiation-hardened chips (BAE Systems, Texas Instruments).
• Ground Infrastructure: High-power amplifiers (Filtronic), RF filters, and fiber connectivity.
• Chips & Compute: Heavy reliance on TSMC, Amkor (packaging), and power management ICs (Monolithic Power).
• Software & Data: Cybersecurity and cloud infrastructure (Palantir, Cloudflare, AWS).

3. SpaceX-Adjacent Stocks (The "Rerated" List)

The speaker highlights five companies already benefiting from the SpaceX narrative:

1. Intuitive Machines (LUNR): Lunar lander developer; 5x revenue growth projected by 2026; first to potentially reach positive adjusted EBITDA.
2. AST SpaceMobile (ASTS): Developing space-based cellular broadband; 1,500% revenue growth (2024–2025); backed by major telecoms (AT&T, Verizon).
3. Planet Labs (PL): Earth imaging satellite fleet; 98% recurring revenue; high-quality, predictable software-like business model.
4. Filtronic (FTC/LTCF): British manufacturer of E-band amplifiers for Starlink; SpaceX holds warrants for up to 15% of the company.
5. Rocket Lab (RKLB): The closest public competitor to SpaceX; developing the "Neutron" rocket; $1.85 billion backlog.

4. The Undervalued Opportunity: Redwire Corporation (RDW)

The speaker identifies Redwire (RDW) as the most undervalued play in the sector.

• The Technology: Their ROSA (Roll-Out Solar Array) technology replaces heavy, rigid panels with lightweight, rollable arrays that use stored strain energy.
• The Connection: ROSA technology is currently powering the International Space Station (ISS) and has been delivered via SpaceX Dragon missions.
• Valuation Gap: Trading at ~5.5x trailing revenue, compared to Rocket Lab (75x) and Planet Labs (43x).
• Catalysts: 41% projected revenue growth, defense contracts (US Navy/Marine Corps), and involvement in the Artemis program.

---

5. Sponsored Segment: Medicus Pharma (MDCX)

Medicus Pharma is developing Skinject, a micro-needle patch for Basal Cell Carcinoma (BCC), the most common form of cancer in the U.S.

• The Problem: Standard treatment (Mohs surgery) is invasive and causes cosmetic disfigurement.
• The Solution: A dissolvable micro-needle patch delivering Doxorubicin directly to the tumor.
• Clinical Status: Phase 2 trial results showed 73% clinical clearance in the 200mcg cohort. The company is pursuing a 505(b)(2) regulatory pathway to accelerate FDA approval.
• Secondary Pipeline: Acquired "Ant Limited" to develop Tavlex, a next-gen GnRH antagonist for prostate cancer, which aims to reduce cardiovascular risks associated with current treatments.

---

Synthesis/Conclusion

The SpaceX IPO represents a massive shift in capital allocation toward the space sector. While Wall Street is currently bidding up stocks based on narrative proximity, the most prudent strategy involves identifying companies with documented supply chain integration and undervalued fundamentals. Redwire (RDW) stands out as a prime example of a company with significant technical utility and growth potential that has yet to be fully priced in by the market. Investors are cautioned to perform rigorous due diligence, particularly with high-risk, clinical-stage biotech firms like Medicus Pharma.